Načítá se...
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection
BACKGROUND: Optimal patient selection would improve the risk-benefit ratio of natalizumab treatment for relapsing-remitting multiple sclerosis (RR MS). Clinical features of subjects responding to natalizumab have not been univocally recognized. METHODS: Longitudinal data on RR MS patients treated wi...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4045962/ https://ncbi.nlm.nih.gov/pubmed/24885703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-14-103 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|